Developing therapeutic antibodies for alzheimer's disease
Ended Project Grant Awarded Last action
- Award ID
- R43AG078094
- Recipient
-
Versapeutics Inc. UEI EGSGJKXHKBN5
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $498,534
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Place of performance
- San Diego, CA 92121, USA
Award details come from USAspending.gov.
Description
- Abstract
- Millions of americans suffer from alzheimer's disease and there are currently no therapies available to prevent or slow the progression of the disease. The unmet medical needs of individuals with alzheimer's disease result in hundreds of billions of dollars of costs in paid and unpaid caregiving in the united states every year. Versapeutics is a small business developing novel therapeutics for alzheimer's disease. In this phase I sbir project we will perform preclinical studies to determine the feasibility of antibody-based therapeutics that are designed to treat alzheimer's disease using a unique mechanism of action, by examining pharmacokinetics, efficacy, toxicity and toxicokinetic. At the conclusion of these studies, we will have met several important milestones that will support further preclinical development of our novel therapeutics for alzheimer's disease.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $498,534 |
Quick answers
Who received award R43AG078094?
R43AG078094 was awarded to Versapeutics Inc. by National Institute on Aging (National Institutes of Health) on July 28, 2022.
How much is award R43AG078094 worth?
$498,534 has been obligated on R43AG078094.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award